INVENTIVA
Biotechnology · Healthcare
Analyst
Piper Sandler
Equibles does not estimate personal net worth.
Yasmin Rahimi is recorded as Analyst at Piper Sandler. Yasmin Rahimi has spoken on 8 earnings calls and 2 other investor events across 10 companies, most recently for INVENTIVA on September 28, 2026. Those appearances were for INVENTIVA, Praxis Precision Medicines, Inc. (PRAX), Madrigal Pharmaceuticals, Inc. (MDGL), Oruka Therapeutics, Inc. (ORKA), BioAge Labs, Inc. (BIOA) and 5 other companies. The companies whose calls Yasmin Rahimi spoke on are classified in the Healthcare sector.
“And thank you so much for walking us through some of the key questions. Maybe we've been lately getting questions from investors.”
“Congrats to an incredible update that I think was very, very timely and important to us, especially as some bears have been creating some noise around, you know, APCOM.”
“Congrats, team, to a strong quarter and also really great news on hearing growth from that to go down is one of our favorite questions. But let's maybe transition to Maestro outcome.”
“So, maybe help us understand on the PASI 100 and PASI 90 scores, like sort of what the air bars look like, specifically around PASI 100, if you had, you know, some patients who might have been, like, was it pretty uniform as you went from week 4 to week 16?”
“The first one is help us understand what, you know, obviously between 60 and 120, both look very, very good. The rationale for selecting 90-mig dose group in your POC cardiovascular study.”
Piper Sandler
Analyst
Transcript header (unverified)
INVENTIVA
Biotechnology · Healthcare
BIOA
Drug Manufacturers - Specialty & Generic · Healthcare
NKTR
Biotechnology · Healthcare
Crinetics Pharmaceuticals, Inc.
Biotechnology · Healthcare
IMVT
Biotechnology · Healthcare
ANAB
Biotechnology · Healthcare
Inventiva H1 2026 financial report
INVENTIVA
Crinetics Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Crinetics Pharmaceuticals, Inc.